Clinical Significance of the RNP Antibody in Systemic Sclerosis Patients_West China Medical Journal

Authors：

West China Hospital of Sichuan University, Chengdu 610041, China;

Corresponding author：

Keywords：

硬皮病; RNP抗体; ENA抗体

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的:分析并探讨RNP抗体在系统性硬化病中的临床意义。方法:收集自2004年以来在我院做过皮肤活检,并通过病理和临床确诊为系统性硬化病的62例住院患者。分为RNP+组(20例),SCL-70+组(20例),ENA-组(22例)。结果:RNP+组较其它两组关节痛、雷诺现象发生率明显升高(P lt;0.05),肌炎发生率亦有升高,指端病变发生率明显降低(P lt;0.05)。结论:通过对系统性硬化病患者体内部分典型抗体的研究,有利于临床医生判断不同抗体阳性的系统性硬化瘤患者病情的严重程度和预后。

Citation： YE Yang,LI Min,SHI Lianjie,et al. Clinical Significance of the RNP Antibody in Systemic Sclerosis Patients. West China Medical Journal, 2009, 24(8): 2070-2072. doi: Copy

1.	叶任高.内科学[M].第6版,北京:人民卫生出版社,2004:933-933..
2.	MASI A T, RODNAN G P, MEDESGER T A. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee[J]. Arthritis Rheum,1980,23(5):581-590.
3.	STEEN V D, MEDSGER TA J R, RODNAN G P. DPenicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis[J]. Ann Intern Med,1982,97(5):652-659.
4.	JACOBSEN S, HALBERG P, ULLMAN S. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis[J]. Br J Rheumatol,1998,37(1):39-45.
5.	IHN H, YAMANE K, YAZAWA N. Distribution and antigen specificity of antiU1RNP antibodies in patients with systemic sclerosis[J]. Clin Exp Immunol,1999,117(2):383-387.
6.	OKANO Y, STEEN V D, MEDSGER T A. Autoantibody to U3 nuclerolar ribonucleoprotein(fibrillarin) in patients with systemic sclerosis[J]. Arthritis Rheum,1992,35(1):95-100.
7.	JACOBSEN S, ULLMAN S, SHEN G Q. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with sclerosis[J]. J Rheumatol,2001,28(11):2454-2459.

1. 叶任高.内科学[M].第6版,北京:人民卫生出版社,2004:933-933..
2. MASI A T, RODNAN G P, MEDESGER T A. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee[J]. Arthritis Rheum,1980,23(5):581-590.
3. STEEN V D, MEDSGER TA J R, RODNAN G P. DPenicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis[J]. Ann Intern Med,1982,97(5):652-659.
4. JACOBSEN S, HALBERG P, ULLMAN S. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis[J]. Br J Rheumatol,1998,37(1):39-45.
5. IHN H, YAMANE K, YAZAWA N. Distribution and antigen specificity of antiU1RNP antibodies in patients with systemic sclerosis[J]. Clin Exp Immunol,1999,117(2):383-387.
6. OKANO Y, STEEN V D, MEDSGER T A. Autoantibody to U3 nuclerolar ribonucleoprotein(fibrillarin) in patients with systemic sclerosis[J]. Arthritis Rheum,1992,35(1):95-100.
7. JACOBSEN S, ULLMAN S, SHEN G Q. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with sclerosis[J]. J Rheumatol,2001,28(11):2454-2459.

West China Medical Journal

Clinical Significance of the RNP Antibody in Systemic Sclerosis Patients

Abstract Full text Figures/Tables Video References Cited by

Format

Content